Ned Warner, DO
Gastroenterology · Idaho Falls, IDNPI 1235175027
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 411 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 35.6% of the total.
Across 411 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$733
- Bristol Myers Squibb$449
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$348
- Gilead$278
- Braintree Laboratories, Inc.$254
- plus $2K from 28 others
Across 41 payments — averaging $3854.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$84K
- Takeda Pharmaceuticals U.S.A., Inc.$28K
- Astrazeneca UK Limited$20K
- Janssen Research & Development, LLC$18K
- Amgen$9K
What the payments were for
- Food & beverage$6,796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 170 | $2,420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $733 |
| Bristol Myers Squibb | 26 | $449 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $348 |
| Gilead | 16 | $278 |
| Braintree Laboratories, Inc. | 8 | $254 |
| Regeneron Healthcare Solutions, Inc. | 12 | $218 |
| Sanofi | 11 | $204 |
| Ferring Pharmaceuticals Inc. | 11 | $165 |
| Intercept Pharmaceuticals, Inc. | 8 | $144 |
| Ardelyx, Inc. | 7 | $131 |
| QOL Medical, LLC | 6 | $128 |
| Johnson & Johnson | 6 | $121 |
| Pfizer | 8 | $121 |
| Phathom Pharmaceuticals, Inc. | 8 | $120 |
| Nestle Healthcare Nutrition Inc. | 5 | $98 |
| Alfasigma USA, Inc. | 6 | $94 |
| Medtronic | 4 | $80 |
| Merck | 4 | $75 |
| Redhill Biopharma Inc. | 3 | $64 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Aimmune Therapeutics, Inc. | 3 | $57 |
| Boston Scientific | 3 | $53 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Fresenius Kabi USA, LLC | 3 | $50 |
| Pentax Of America, Inc. | 1 | $49 |
| Shield Therapeutics Inc | 2 | $44 |
| Shire North American Group Inc | 2 | $41 |
| Meridian Bioscience Inc. | 1 | $35 |
| Amgen | 2 | $27 |
| Celltrion USA Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Organon | 1 | $16 |
| Biocon Biologics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUFLAVE$122
How this compares
$6,796 in reported general payments places this provider in the 85th percentile of 70 gastroenterology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 32 | $212,873 |
| XifaxanRifaximin | 68 | $201,590 |
| OcalivaObeticholic Acid | 11 | $103,552 |
| LinzessLinaclotide | 32 | $21,914 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 188 | $12,505 |
| Mesalamine ErMesalamine | 23 | $8,402 |
| Ondansetron Hcl | 34 | $8,007 |
| Budesonide DrBudesonide | 17 | $6,871 |
| Mesalamine | 11 | $4,678 |
| MovantikNaloxegol Oxalate | 11 | $4,301 |
| Omeprazole | 403 | $3,811 |
| Lubiprostone | 26 | $3,577 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,740 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 40 | $1,268 |
| Dicyclomine Hcl | 67 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $348 | $201,59068 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $144 | $103,55211 claims |
| AbbVieLinzess | $2,420 | $21,91432 claims |
| Redhill Biopharma Inc.Movantik | $64 | $4,30111 claims |
| Braintree Laboratories, Inc.Sutab | $254 | $1,74011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 70 gastroenterology providers in Idaho.
Other gastroenterology in Idaho Falls
- Todd WilliamsIdaho Falls$8K
- Larry EvansIdaho Falls$7K
- Michael RichinsIdaho Falls$6K
- Clint BehrendIdaho Falls$4K
- Paul HendrixIdaho Falls$2K
- Jacob WendlingIdaho Falls$421
- David JohnsonCoeur D Alene$190K
- Matthew SericatiBoise$111K
- Ashley EvansBoise$69K
- Bryan BrimhallBoise$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.